MNPR   $20.2  2.49% Market Closed After Close 19.6512 -2.72%

Monopar Therapeutics Inc
Last Events:

2023-08-09 Signal in Stochastic changed from bullish to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-05 Trend pattern changed from нисходящий треугольник to нисходящий клин.

2023-08-05 Signal in MACD changed from bearish weakening to bullish reversal. Oscillator MACD is in the negative territory it crossed the signal line from the bottom and grows. These factors mean that the market confirms the end of the downward trend. Last signal: main and signal line crossing.

2023-08-04 Signal in MACD changed from bearish recovery to bearish weakening. Oscillator MACD is in the negative territory it's lower than the signal line and grows. These factors mean that the falling trend persists, but the growth rate is declining. Last signal: main and signal line crossing.

2023-08-04 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-03 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: main and signal line crossing.

2023-08-03 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.


Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 3
Target Price Mean 27.33
Mean unverified/preliminary 27.33 / 27.33
Target Price Low / High 22.00 / 37.00
Median / STD DEV 23.00 / 8.39
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy ActivelyBuy ActivelyBuy
rsi Sell ActivelyBuy None
macd None None None
stoch ActivelyBuy None None
ma20 ActivelyBuy ActivelyBuy ActivelyBuy
ma50 None None None
ma100 ActivelyBuy ActivelyBuy None
Candlestick PatternOct. 24, 2024 Three Crows - is a candlestick pattern that consists of three long black candlesticks with consecutively lower closes. The closing prices are near to or at their lows. Considered to be a bearish reversal pattern.
ISIN US61023L2079
ceo Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Website https://www.monopartx.com
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.